Dr. Reddy's Laboratories Reports Q1 Revenue Decline Amid Semaglutide and Lenalidomide Challenges
Dr. Reddy's Laboratories reported a year-over-year revenue decline of 5.6% to INR 8,071 crores for the first quarter of fiscal 2027 due to lower lenalidomide sales and semaglutide API disruptions. The company recorded an EBITDA margin of 12.5%, down from a provision of INR 240 crores related to these issues, though it expects improved performance in the second half.
Topics: ebitda lenalidomide pharmaceuticals revenue semaglutide